Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies

Introduction: Janus kinase inhibitors (JAK-i), a class of targeted synthetic disease-modifying antirheumatic drugs (tDMARDs), are suggested as second or third-line therapies in rheumatoid arthritis (RA). Synthesized cost-effective evidence would aid in informed decision-making given the similar clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, S. Sajith, Haridoss, Madhumitha, Venkataraman, Krishnamurthy, Bagepally, Bhavani Shankara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792993/
https://www.ncbi.nlm.nih.gov/pubmed/36582538
http://dx.doi.org/10.3389/fphar.2022.1090361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792993/
https://www.ncbi.nlm.nih.gov/pubmed/36582538
http://dx.doi.org/10.3389/fphar.2022.1090361

Ejemplares similares